Page 2 - Read Online
P. 2
Topic: The Interplay between
Direct-Acting Antivirals and
Hepatocellular Carcinoma in
Chronic Hepatitis C
Hepatocellular carcinoma (HCC) is the second cause
of cancer-related death worldwide. Hepatitis C virus
(HCV) infection is one of the leading etiologies of
HCC, which accounts for one-third of HCC patients.
Direct-acting antivirals (DAAs), the standard of care
for chronic hepatitis C (CHC), are anticipated to reduce
the risk of HCV-related HCC. Unlike interferon-based
treatment cohort studies, some debates exist between
the interplay of DAA and HCC due to the relatively
short follow-up period diverse patient characteristics
Prof. Ming-Lung Yu, and different mechanisms of action. As a consequence,
MD, PhD unsolved issues include the beneficial effect of HCC
Senior Vice President, Kaohsiung risk reduction by DAAs compared to interferon-based
Medical University, Kaohsiung, regimens, and the impact of DAAs on HCC recurrence
Taiwan in terms of the incidence and tumor behaviors.
Distinguished Professor, Hepatobiliary Meanwhile, whether the existence of HCC compromises
Section, Department of Internal
Medicine, and Hepatitis Center, DAAs treatment efficacy is also an area of interest.
Kaohsiung Medical University Risk factors of HCC occurrence and recurrence from
Hospital, Kaohsiung Medical the demographic, genetic and metabolic aspects have
University, Kaohsiung, Taiwan
also been raised in the DAA era. The current issue
“The Interplay between Direct-Acting Antivirals
and Hepatocellular Carcinoma in Chronic Hepatitis
C” will cover the abovementioned topics and provide
thorough information for the readers.
